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Phase I of the Surveillance for Enteric Fever in Asia Project 
(SEAP): An Overview and Lessons Learned
Caitlin Barkume,1 Kashmira Date,2 Samir K. Saha,4 Farah Naz Qamar,5 Dipika Sur,6 Jason R. Andrews,3 Stephen P. Luby,3 M. Imran Khan,1,a  
Alex Freeman,1,b Mohammad Tahir Yousafzai,5 and Denise Garrett1
1Typhoid Programs, Sabin Vaccine Institute, Washington, D. C.; 2Global Immunization Division, Centers for Disease Control and Prevention, Atlanta, Georgia; 3Infectious Diseases 
and Geographic Medicine, Stanford University, California; 4Child Health Research Foundation, Department of Microbiology, Dhaka Shishu (Children) Hospital, Bangladesh; 
5Department of Pediatrics and Child Health, Aga Khan University, Karachi, Pakistan; and 6Translational Health Science and Technology Institute, Faridabad, India 
Objective. The objective of Phase I of the Surveillance for Enteric Fever in Asia Project (SEAP), a multiphase surveillance study 
characterizing the burden of disease in South Asia, was to inform data collection for prospective surveillance and to capture clinical 
aspects of disease.
Methods. Through a retrospective record review conducted at hospitals in Bangladesh, India, Nepal, and Pakistan, we examined 
laboratory and clinical records to assess the culture positivity rate for Salmonella Typhi and Salmonella Paratyphi, age and sex distri-
bution, and antimicrobial susceptability in each country.
Results. Of all blood cultures performed in Bangladesh, India, Nepal, and Pakistan, 1.5%, 0.43%, 2%, and 1.49%, respectively, 
were positive for S. Typhi and 0.24%, 0.1%, 0.5%, and 0.67%, respectively, were positive for S. Paratyphi. A higher proportion of 
laboratory-confirmed infections in Bangladesh and Pakistan were aged ≤5  years, while India and Nepal had a higher propor-
tion of participants aged 15–25 years. In all countries, the sex of the majority of participants was male. The majority of isolates 
in all countries were resistant to fluoroquinolones, with a high proportion also resistant to ampicillin, chloramphenicol, and 
trimethoprim-sulfamethoxazole.
Discussion. Enteric fever remains endemic in South Asia. Data generated by this study can help inform strategies for implemen-
tation and evaluation of prevention and control measures.
Keywords. Typhoid; paratyphoid; enteric fever; Salmonella; South Asia; antimicrobial resistance.
 
Enteric fever, a preventable illness caused by the organisms 
Salmonella enterica subspecies enterica serovar Typhi or serovar 
Paratyphi, is estimated to cause >15 million illnesses and nearly 
153 000 deaths worldwide annually [1, 2]. These organisms are 
transmitted through food and water contaminated with fecal 
matter, and their control ultimately depends on access to pota-
ble water, as well as safely managed sanitation and hygienic 
practices in homes and in food production. Vaccines that pro-
tect against typhoid fever have been available for many years, 
and in March 2018, the World Health Organization (WHO) 
recommended the use of a newly prequalified typhoid conju-
gate vaccine (TCV) for typhoid fever prevention in countries of 
endemicity [3]. Compared with the 2 previously available vac-
cines, TCV provides longer-lasting protection, requires fewer 
doses, and is additionally suitable for children aged 6 months to 
<2 years, allowing delivery through routine childhood immuni-
zation programs [3–5]. Furthermore, the TCV was included in 
the 2019–2020 funding window of Gavi, the Vaccine Alliance 
[6]. To deliver the TCV to susceptible populations, it requires 
the support of country governments in many low- and mid-
dle-income countries, as well as other stakeholders, such as 
Gavi, the Vaccine Alliance. However, the absence of credi-
ble estimates of the burden of disease has made it difficult to 
provide policymakers with accurate estimates of the cost and 
potential impact of targeted interventions for prevention and 
control of enteric fever, including TCV.
One contributing factor to uncertainty about the burden of 
disease is the lack of reliable diagnostic testing. The most con-
sistently valid method for laboratory diagnosis is blood culture, 
estimated to be only 61% sensitive [7] in a recent meta-analysis, 
and may be dependent on sample volume [8]. In many low- and 
middle-income countries, blood culture is also largely unavail-
able, particularly in rural areas. Additionally, the widespread 
use of antibiotics to treat typhoid empirically may reduce the 
sensitivity of blood culture and further reduce estimates of dis-
ease burden; in Nepal, 35% of participants had taken antibiotics 
prior to seeking healthcare at the study hospitals [9].
Over the last 2 decades, several surveillance studies have 
attempted to characterize the burden of enteric fever, includ-
ing the Diseases of the Most Impoverished Program and 
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the Typhoid Fever Surveillance in Africa Program [10, 11]. 
While these studies were among the first prospective, popula-
tion-based studies that estimated the incidence of enteric fever 
in Asia and sub-Saharan Africa, they have left several knowl-
edge gaps, including the incidence of specific complications 
and the spectrum of disease and severity. Data on the cost of 
illness and the geographic spread of strains, including antimi-
crobial-resistant ones, are also limited. Since these studies, the 
Bill and Melinda Gates Foundation has invested in several new 
surveillance studies, including the Severe Typhoid in Africa 
project and the Surveillance for Enteric Fever in Asia Project 
(SEAP). SEAP is a multiphase enteric fever surveillance study 
designed to fill knowledge gaps about the burden of disease 
in Bangladesh, India, Nepal, and Pakistan. With the ability to 
characterize the burden of enteric fever in 3 major cities and 1 
peri-urban area within the selected countries, results from this 
project will be able to help inform the use of TCVs and other 
typhoid prevention and control efforts.
The project has 2 phases: Phase I, a retrospective record 
review, and Phase II, a prospective study with defined enroll-
ment criteria, including specific case definitions. Phase I had 3 
objectives: (1) identify site hospitals in selected countries where 
enteric fever is endemic, to assess the burden of disease through 
record review and inform data collection for Phase II surveil-
lance; (2) ensure that the hospital had capacity to participate in 
Phase II surveillance; and (3) map cases geographically to con-
firm the feasibility of creating a well-defined catchment area for 
each hospital in which the incidence of enteric disease can be 
estimated during Phase II surveillance. This article will present 
the results of the first objective.
METHODS
Based on the available data in the literature on the geographic 
burden of enteric fever, we chose Bangladesh, India, Nepal, and 
Pakistan as potential country sites.
Study Site Selection
We conducted a standard assessment of existing hospitals, 
health clinics, and laboratories in the area to determine pos-
sible study sites. Key variables in the health facility assess-
ment were as follows: (1) existing evidence on the prevalence 
of enteric fever; (2) a population that is representative of the 
overall demographic and socioeconomic characteristics of 
the surrounding population; (3) a strong laboratory capacity 
and inpatient (medical and surgical) and outpatient facilities; 
(4) a location geographically close to the population served 
by the study hospital; (5) the availability of population-based 
sociodemographic indicators from reliable sources (eg, bureau 
of statistics of the city/district/national level or demographic 
health surveys) or the ability to obtain a geographically repre-
sentative sample, which will allow extrapolation of population 
size and demographic characteristics; and (6) a willingness 
and commitment to conduct the study on the basis of agreed 
upon aims and objectives. Based on this assessment, we chose 
several sites in each country, specified below, for inclusion in 
the study.
Bangladesh
Two sites were selected in Bangladesh: Dhaka Shishu Hospital, a 
640-bed tertiary-care hospital, and Shishu Sasthya Foundation 
Hospital, a 200-bed hospital providing primary care only. Both 
serve a catchment area of 3.4 million people and are the 2 largest 
pediatric hospitals in Dhaka (serving patients aged <18 years). 
Owing to proximity, both hospitals are within the same catch-
ment area, in an urban and peri-urban setting. Both hospi-
tals are also sentinel sites in the WHO-coordinated Invasive 
Bacterial Vaccine-Preventable Disease surveillance network, 
which captures information electronically on hospitalized 
patients with suspected or laboratory-confirmed pneumonia, 
sepsis, and meningitis. The hospitals were able to use this sur-
veillance network to create a platform to capture enteric fever 
cases, which facilitated data collection for Phase I.
India
Five sites were selected in India: the Postgraduate Institute of Medical 
Sciences, a mixed public-private tertiary hospital in Chandigarh 
with 1960 beds; Medanta Hospital, a private tertiary hospital in 
Gurugram (previously known as Gurgaon), Haryana, with 1250 
beds; Christian Medical College, a private tertiary hospital in 
Vellore, Tamil Nadu, with 2800 beds; Apollo Gleneagles Hospital, 
a private tertiary hospital in Kolkata, West Bengal, with 750 beds; 
and Kasturba Medical College  –  Manipal University  Hospital, a 
private tertiary hospital in Manipal, Karnataka, with around 2000 
beds. All sites serve urban populations, except Kasturba Medical 
College, which serves a peri-urban population.
Nepal
Sites were chosen because of a prospective enteric fever surveil-
lance study already in place [9], which facilitated data collection. 
The 4 selected sites were: Bayalpata Hospital, a 15-bed hospital 
serving a rural population in Achlam; Damauli Hospital, a dis-
trict hospital serving the town of Vyas, which has a population 
of 43 000; Kirnetar Health Center, a clinic in rural Dolakha; and 
Dhulikhel Hospital in Kavrepalanchowk, serving a peri-urban 
population in the greater Kathmandu Valley and with catch-
ment area of approximately 330 000 people.
Pakistan
Three sites in Pakistan were selected, consisting of the 3 hospi-
tals in the Aga Khan University Hospital network: Aga Khan 
University Hospital, a 700-bed tertiary care hospital in Karachi; 
Aga Khan Hospital for Women and Children, a 48-bed second-
ary care hospital in Karachi; and Aga Khan Hospital Hyderabad, 
an 87-bed secondary care hospital in Hyderabad. Both Aga 
Khan Hospital for Women and Children and Aga Khan Hospital 
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Hyderabad only provide care for women and children. These 
hospitals cover a catchment area of 3 million people.
Study Period, Data Sources, and Case Definitions
After site selection was completed, we conducted a retrospective 
review of data available on enteric fever from the selected hospi-
tals, including suspected cases and blood culture–confirmed S. 
Typhi and S. Paratyphi infection. A minimum of 2 years of data 
were collected to assess any seasonal variation at the selected 
sites. Specific methods for the sites, including case definitions, 
study periods, and data sources, are described in Table 1.
Data Collection and Analysis
Laboratory Data Collection
For each month of data collection, the following information 
was obtained from laboratories: the number of blood cultures 
performed, the number of blood cultures positive for S. Typhi 
and S. Paratyphi, and any available patient-level demographic 
information, such as age, sex, neighborhood of residence, and 
specimen collection date. For the retrospective phase, patient 
address was only collected up to the smallest administrative 
unit, to map the catchment area. For Bangladesh and Nepal, 
data were extracted retrospectively from prospective studies 
already in place.
Inpatient Department Data Collection
Using hospital record numbers and where available, study staff 
obtained charts of hospitalized participants with laboratory-con-
firmed S. Typhi or S. Paratyphi infection and abstracted clinical 
information, including demographic characteristics, treatments, 
investigations, clinical manifestations, and patient outcomes.
Data were abstracted using standard instruments and entered 
electronically for analysis, which was performed at the coun-
try level. Differences in sex and age distributions were analyzed 
using Wilcoxon rank sum tests and differences in proportions. 
Blood culture positivity rates and antimicrobial resistance pat-
terns were descriptively reviewed. More details about the anal-
yses performed are available in the country-specific articles 
published in this supplement [9, 12–14].
Ethical Review
The study protocols were reviewed and approved by the Centers 
for Disease Control and Prevention (Atlanta, GA); institu-
tional ethics committees at Translational Health Science and 
Technology Institute (Faridabad, India), the Postgraduate 
Institute of Medical Sciences (Chandigargh, India), Medanta 
Hospital (Gurugram, India), Apollo Gleneagles Hospital 
(Kolkata, India), Kasturba Medical College – Manipal University 
Hospital (Manipal, India); the Institutional Review Board at 
Christian Medical College (Vellore, India); the Institutional 
Review Board for Human Subjects Research of the Nepal 
Health Research Council (Kathmandu, Nepal); the Kathmandu 
University School of Medical Sciences Institutional Review 
Committee (Dhulikhel, Nepal); Partners Human Research 
Committee (Boston, MA); the University Health Network 
Research Ethics Board (Toronto, Canada); the Stanford 
University Institutional Review Board (Stanford, CA); the 
Ethical Review Committee of Aga Khan University (Karachi, 
Table 1.  Sentinel Healthcare Facilities, Study Period, Case Definitions, and Data Sources in Bangladesh, India, Nepal, and Pakistan, Surveillance for 
Enteric Fever in Asia Project (SEAP) Phase I, 2012–2016
Country Sentinel Healthcare Facilities Study Period Case Definitions Data Sources
Bangladesh Dhaka Shishu Hospital and Shishu Sasthya 
Foundation Hospital, Dhaka
January 2013– 
December 2014
Suspected case: a patient with a final 
clinical diagnosis of enteric fever 
without laboratory confirmation of 
S. Typhi or S. Paratyphi infection 
through blood culture;
Laboratory-confirmed case: a patient 
with S. Typhi or S. Paratyphi iso-
lated from the blood by culture
Laboratory and clinical records of hos-
pitalized laboratory-confirmed cases
India Postgraduate Institute of Medical Sciences, 
Chandigarh; Medanta Hospital, New 
Delhi; Apollo Hospital, Kolkata; Kasturba 
Medical College – Manipal University 
Hospital, Manipal and
Christian Medical College, Vellore
January 2014– 
December 2015
Laboratory-confirmed case: a patient 
with S. Typhi or S. Paratyphi iso-
lated from the blood by culture;
Surgical case: a patient with intestinal 
perforation regardless of blood cul-
ture confirmation
Laboratory records of laboratory-con-
firmed cases and clinical records of 
hospitalized laboratory-confirmed 
cases and surgical cases
Nepal Bayalpata Hospital, Achlam; Damauli 
Hospital, Vyas; Dhulikhel Hospital, 
Kavrepalanchowk; and Kirnetar Health 
Center, Dolakha
August 2013– 
June 2016
Suspected case: a patient 
>12 months of age presenting to 
the study sites with a self-reported 
>72-hour history of fever;
Laboratory-confirmed case: a patient 
with S. Typhi or S. Paratyphi iso-
lated from blood by culture
Questionnaires administered to 
participants, clinical records, and 
laboratory records of suspect and 
laboratory-confirmed cases
Pakistan Aga Khan University Hospital and Aga 
Khan Hospital for Women and Children, 
Karachi; Aga Khan Hospital Hyderabad, 
Hyderabad
January 2012– 
December 2014
Laboratory-confirmed case: a patient 
with S. Typhi or S. Paratyphi iso-
lated from the blood by culture
Laboratory and clinical records of hos-
pitalized laboratory-confirmed cases
Abbreviations: S. Paratyphi, Salmonella enterica subspecies enterica serovar Paratyphi; S. Typhi, Salmonella enterica subspecies enterica serovar Typhi.
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Pakistan); and the Ethical Review Committee of Bangladesh 
Institute of Child Health (Dhaka, Bangladesh).
Identifying personal information was accessible only to eval-
uation staff at the sites. All data reported to investigators were 
deidentified.
RESULTS
Overall results from sites in each country, including the num-
ber of blood cultures and blood culture positivity rate (total 
and by organism), are shown in Table 2 and described below. 
At the Bangladesh hospitals, 51 923 children were admitted 
to the site hospitals, and of those admitted, 15 917 (31%) had 
blood cultures performed. Nearly 3% (443 of 15 917) were cul-
ture positive for significant bacterial growth, and 63% of these 
isolates (279 of 443) were confirmed to be S. Typhi (241 [86%]) 
or S. Paratyphi (38 [14%]). An additional 1591 children were 
suspected as having enteric fever, yielding 1870 children with 
suspected or confirmed enteric fever. This represents 3.6% of 
all hospital admissions (1870 of 51 923) in both hospitals in the 
2-year period. At all 5 hospitals in India, 267 536 blood cultures 
were performed during the study period, and of these, 1418 
(0.53%) were positive for S. Typhi (1147 [81%]) or S. Paratyphi 
(271 [19%]). In the 4 Nepal sites, 4309 participants were 
enrolled as having suspected infection, of whom 176 (4.1%) 
had a blood culture positive for pathogenic bacteria; 109 (62%; 
2.5% of participants with blood cultures performed) had cul-
tures positive for S. Typhi (87 [80%]) or S. Paratyphi (22 [20%]). 
Among the 133 017 blood cultures performed in the hospitals in 
Pakistan, 2872 (2.2%) were positive for S. Typhi (1979 [69%]) or 
S. Paratyphi (893 [31%]).
The age distributions of participants with laboratory-con-
firmed cases varied between the 4 countries (see Figure  1). 
Bangladesh had the youngest participants for both S. Typhi 
(median, 3  years; interquartile range [IQR], 2–6  years) and 
S. Paratyphi (3  years; IQR, 2–6  years) infection, but this was 
expected as the 2 site hospitals served pediatric patients only. 
In Pakistan, which also captured more pediatric cases, partici-
pants with S. Typhi infection were significantly younger, com-
pared with S. Paratyphi–infected participants (median, 7 years 
[IQR, 3–13  years] vs 15  years [IQR, 6–25  years]; P  <  .0001). 
Nepal, however, had age distributions curves shifted toward 
young adults (median, 19 years [IQR, 14–26 years] for S. Typhi 
infection and 20 years [IQR, 17–24 years] for S. Paratyphi infec-
tion), as did India (median, 24 years [IQR, 14–28 years] for S. 
Typhi infection and 24 years [IQR, 18–30 years] for S. Paratyphi 
infection). The difference in ages between organisms was signif-
icant in India (P = .01) but not in Nepal. In all 4 countries, the 
sex of the majority of the participants was male (68% in India, 
61% in Pakistan, 55% in Bangladesh, and 52% in Nepal).
Antimicrobial resistance patterns for each country, by organ-
ism, are shown in Figure  2. Overall, a higher proportion of 
S. Typhi isolates were resistant to chloramphenicol, ampicil-
lin, and trimethoprim-sulfamethoxazole, compared with S. 
Paratyphi isolates. A high proportion of both S. Typhi and S. 
Paratyphi isolates from all 4 countries were nonsusceptible to 
ciprofloxacin, and a number of isolates exhibited resistance to 
ceftriaxone (1 of 115 S. Typhi isolates in Nepal and 4 of 418 in 
India) and azithromycin (2 of 23 S. Paratyphi isolates in Nepal 
and 2 of 30 S. Typhi isolates and 1 of 3 S. Paratyphi isolates in 
India).
Complete results are available in the country-specific articles 
published in this supplement [9, 12–14].
DISCUSSION
This study generated data on enteric fever prevalence among 
febrile patients, by age, sex, and time (month/year), along with 
information on other clinical factors and antimicrobial resis-
tance among hospitalized participants with enteric fever from 
sentinel sites in 4 countries, allowing for cross-site comparison. 
These results were critical to informing data collection for the 
prospective phase of the SEAP. While prospective surveillance 
will occur in India through a separate surveillance system (the 
National Surveillance System for Enteric Fever in India), we 
have identified sites in Bangladesh, Nepal, and Pakistan that 
continue to experience a sustained burden of enteric fever and 
are capable of contributing useful information on disease bur-
den in prospective surveillance.
In Pakistan, S. Typhi infections were concentrated around 
younger ages, and while Bangladesh had pediatric cases only, 
because the sites were pediatric hospitals, nearly a quarter of 
S. Typhi–infected participants were <2  years old. This is an 
important observation, since these ages represent a population 
that can be protected with TCVs if a vaccination program is 
implemented. While overall the burden has shifted to an older 
Table 2. Blood Culture Positivity Rate Among Individuals With Enteric Fever During Each Country-Specific Study Period, Bangladesh, India, Nepal, and 
Pakistan, Surveillance for Enteric Fever in Asia Project (SEAP) Phase I, 2012–2016
Country Duration of Data Collection, Mo Blood Cultures Performed, No.
Positive Blood Culture Results, No. (%)
S. Typhi Detected S. Paratyphi Detected Overall
Bangladesh 24 15 917 241 (1.5) 38 (0.24) 279 (1.75)
India 24 267 536 1147 (0.43) 271 (0.1) 1418 (0.53)
Nepal 34 4309a 87 (2) 22 (0.5) 109 (2.5)
Pakistan 36 133 017 1979 (1.49) 893 (0.67) 2872 (2.2)
aData are for participants enrolled in an ongoing prospective surveillance study, using a case definition of ≥3 days of fever.
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population in India and Nepal as compared to Pakistan and 
Bangladesh, there remains a considerable burden of S. Typhi 
at the younger ages and a need for TCV implementation; the 
older population would also benefit from the WHO’s recom-
mendation for a catch-up campaign beginning at 15 years [3]. 
These differences in ages should be viewed in the context of the 
study design, though, because the differences could be partially 
explained by trends in healthcare-seeking behavior. This is also 
the case for sex distribution; literature has shown that gener-
ally a higher proportion of males seek care at the hospital, espe-
cially in younger ages [15]. Prospective surveillance performed 
in these countries will allow us to adjust incidence estimates 
based on reported care-seeking behavior and to estimate rates 
of infection by sex and age group.
We were also able to review current patterns of antimicrobial 
resistance in all 4 countries. There is still a high proportion of 
S. Typhi isolates resistant to chloramphenicol, ampicillin, and 
trimethoprim-sulfamethoxazole, especially in Pakistan and 
Bangladesh [12, 14]. Since the proportion of isolates in these 
countries that are nonsusceptible to ciprofloxacin is nearing 
100%, this leaves third-generation cephalosporins, azithromy-
cin, and carbapenems as the last remaining oral antibiotics for 
treating typhoid. As we have identified a few isolates in Nepal 
and India resistant to these agents [9, 13], continued close mon-
itoring of antimicrobial resistance is essential to inform appro-
priate treatment recommendations.
SEAP Phase I has yielded valuable information on the enteric 
fever burden across multiple settings in South Asia, but the 
results are best considered in the context of the chosen study 
settings. There may be an upward bias in incidence estimates 
generated in urban populations when compared with rural pop-
ulations, likely because of transmission drivers such as popula-
tion density and scarce access to clean water and sanitation [16]. 
Indeed, data from the Nepal study described in this supplement 
found that the prevalence of enteric fever among febrile individ-
uals was strongly correlated with population density [9].
In addition to limitations in in-country generalizability 
due to the selected sites, SEAP Phase I provides an important 
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Figure 1. Age distribution of enteric fever cases in Bangladesh (A), India (B), Pakistan (C), and Nepal (D), Surveillance for Enteric Fever in Asia Project (SEAP) Phase I, 
2012–2016. S. Paratyphi, Salmonella enterica subspecies enterica serovar Paratyphi; S. Typhi, Salmonella enterica subspecies enterica serovar Typhi.
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perspective on key issues and limitations of retrospective data. 
Data obtained were limited in terms of comparability across 
settings and period. The data from each setting were highly 
variable with regard to availability, including variability for the 
surveillance period, age groups included in surveillance, and 
surveillance methods. Perhaps most significant was the vari-
ability in case definitions used for participants with suspected 
cases for whom a blood culture was requested. The lack of stan-
dardized criteria for requesting blood culture makes the diag-
nosis of enteric fever highly subjective to the treating clinicians’ 
opinions. This is illustrated in Nepal, where half of individu-
als with a fever duration of >3 days were given a provisional 
clinical diagnosis of typhoid, but fewer than 5% of these indi-
viduals had culture-confirmed infection [9]. Furthermore, cli-
nicians in resource-poor settings may be less likely to prescribe 
testing for poorer patients, who are possibly at a higher risk 
of enteric fever and subsequent poor outcomes. Additionally, 
hospital-based studies have an inherent limitation in that they 
underestimate the disease burden in the community, owing to 
differential health-seeking behaviors [17]. Active, communi-
ty-based surveillance, is also more likely to be able to identify 
complications and sequelae that occur in patients with typhoid 
fever after discharge from a hospital or treatment at an outpa-
tient clinic. These limitations and others [18], combined with 
nonstandardized case definitions, have important implications 
for disease burden and incidence estimations, which form 
the basis of national and global policies [1, 2]. The data from 
Phase I were also limited to what was available retrospectively 
through existing data sources, primarily clinical records from 
a few sites. While laboratory data were relatively more com-
plete and available, linking laboratory and clinical data sources 
presented difficulties. Clinical records were either missing or 
did not adequately capture the required information for a large 
proportion of laboratory-confirmed cases, specifically among 
individuals seen in outpatient departments. This prohibited 
sufficient characterization of the clinical profile of laborato-
ry-confirmed cases and differences in clinical profiles by anti-
microbial resistance. This is an especially critical lesson learned 
in the era of rising antimicrobial resistance and a potentially 
increased severity of illness associated with resistant strains 
[19–21].
Phase II of the SEAP will address many of these limitations 
inherent to retrospective study design. For example, the pro-
tocol for Phase II has a clearly defined study population, using 
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Figure 2. Antimicrobial resistance patterns among Salmonella enterica subspecies enterica serovars Typhi (A) and Paratyphi (B) isolates in Bangladesh, India, Nepal, and 
Pakistan, Surveillance for Enteric Fever in Asia Project (SEAP) Phase I, 2012–2016. aReduced susceptibility; nalidixic acid was used as a proxy in Bangladesh.
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a created catchment area to define eligibility, and standardized 
case definitions, which differ by enrollment location within the 
hospital (eg, outpatient, inpatient, and surgical settings). We 
also plan to prospectively collect robust data through multiple 
sources, including patient interviews, laboratory records, and 
medical charts, to improve the quality and amount of avail-
able information and its potential to be appropriately linked 
and analyzed. Unlike Phase I, Phase II will be able to estimate 
incidence on the basis of data from hospital-based surveillance, 
using the low-cost hybrid method outlined by Luby et al [17]. 
We plan to obtain the proportion of participants with disease 
matching our case definition who sought healthcare and create 
age-stratified incidence by using healthcare-seeking behavior, 
as well as to adjust for a variety of factors related to potential 
biases as described by another article in this supplement [22], to 
deliver more-discrete and accurate estimates to country govern-
ments and decision makers.
SEAP Phase I is one of the few multicenter studies in South 
Asia that have attempted to retrospectively assess the enteric 
fever burden by using existing clinical and disease surveillance 
systems. With investment in capacity building, SEAP is build-
ing a low-cost and sustainable surveillance system that can be 
leveraged for ongoing surveillance to evaluate the impact of 
interventions, including vaccines, by integrating data capture 
into existing site infrastructure. It is unlikely that vaccines will 
entirely eliminate typhoid, shown by modeling in South Asia, 
but that a combination of water, sanitation, and hand hygiene 
interventions and vaccination may eliminate typhoid in set-
tings where it is endemic [23]. Since the recent availability of 
a licensed and WHO-prequalified typhoid conjugate vaccine 
(Typbar-TCV; Bharat Biotech, India), which has been shown 
to be immunogenic in children aged <2 years, demonstrating 
vaccine effectiveness and public health impact is more import-
ant than ever [5, 24–26]. SEAP Phase II will produce not only 
accurate estimates of the burden of disease in selected areas 
in Bangladesh, Nepal, and Pakistan, but also baseline data 
for future vaccine effectiveness studies in the site catchment 
areas, as well as evaluate the impact of additional long-term 
interventions, such as improvements in water and sanitation 
infrastructure.
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